In the newest Making Medicine, Patrick Jordan likens MFN drug pricing to a mismatched organ transplant -- well-intentioned, but doomed long-term. The U.S. health care system is fundamentally different from the rest of the world, so a one-size-fits-all policy doesn't work.

Many countries set drug prices using comparators. That's like pricing a 4K smart TV the same as an old-school RCA because they're both "TVs." In Making Medicine, John Stanford unpacks the realities of importing MFN pricing. See the full episode on YouTube.

On the newest edition of Making Medicine, John Stanford covers industry headlines: Trump's pharma tariffs and drug pricing push, biotech IPOs, & NIH cuts. We also debut a new FDA Approvals corner. Watch the full episode on YouTube: youtube.com/watch?v=P6RH02…

On the newest Making Medicine, John Stanford sits down with Kendalle Burlin O'Connell, @MassBIO CEO & president, to break down the MassBIO 2025 Industry Snapshot and explore how policy decisions are shaping biotech investment in Massachusetts. Full episode on YouTube: youtu.be/cvYlplqW37I?fe…

On this week's Making Medicine, guest Max Bayer warns that biotech is at a crossroads: the U.S. saw its first net loss in biotech jobs in years, while China pours resources into growing its ecosystem. Watch the full episode on YouTube.

On the latest Making Medicine, Max Bayer highlights the wave of actions facing drugmakers: MFN deadlines, tariff pressures, and possible executive moves involving out-licensing from China. See the full episode on YouTube.

On a new episode of Making Medicine, John Stanford shares that biotech leaders are feeling the weight of policy uncertainty, citing that "many executives and investors said what is happening in Washington makes it very, very hard to invest."

On Making Medicine, John Stanford shares what he's hearing in Boston: fewer international students, shrinking biotech pipelines, and fears of a growing "brain drain." Biotech is hard -- America needs to show young scientists that their work and talent matter here.

ICYMI: On Making Medicine's FDA Approvals Corner, John Stanford shared recent FDA approvals, celebrating important advances for patients with rare diseases and cancer. Watch here: youtube.com/watch?v=kld5KK…

HHS, FDA, and CMS leaders announced new steps this week to simplify biosimilar approvals, potentially reducing clinical testing requirements and speeding market entry for more affordable therapies. John Stanford covers this and more on the latest edition of Making Medicine: